AGIOS PHARMACEUTICALS INC's ticker is AGIO and the CUSIP is 00847X104. A total of 221 filers reported holding AGIOS PHARMACEUTICALS INC in Q2 2018. The put-call ratio across all filers is 0.59 and the average weighting 0.2%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q1 2022 | $782,000 | -51.9% | 26,864 | -45.7% | 0.00% | -100.0% |
Q4 2021 | $1,626,000 | -53.1% | 49,475 | -34.1% | 0.00% | -50.0% |
Q3 2021 | $3,467,000 | -53.0% | 75,124 | -43.8% | 0.00% | -50.0% |
Q2 2021 | $7,369,000 | +2.8% | 133,712 | -3.6% | 0.00% | 0.0% |
Q1 2021 | $7,165,000 | +5.4% | 138,751 | -11.5% | 0.00% | 0.0% |
Q4 2020 | $6,796,000 | +36.7% | 156,853 | +10.4% | 0.00% | 0.0% |
Q3 2020 | $4,972,000 | -44.2% | 142,059 | -14.8% | 0.00% | -42.9% |
Q2 2020 | $8,914,000 | +126.8% | 166,684 | +50.4% | 0.01% | +75.0% |
Q1 2020 | $3,931,000 | -10.5% | 110,808 | +20.5% | 0.00% | +33.3% |
Q4 2019 | $4,390,000 | +196.4% | 91,944 | +101.2% | 0.00% | +200.0% |
Q3 2019 | $1,481,000 | -46.2% | 45,703 | -17.2% | 0.00% | -50.0% |
Q2 2019 | $2,754,000 | -14.0% | 55,204 | +16.2% | 0.00% | -33.3% |
Q1 2019 | $3,203,000 | +64.1% | 47,495 | +12.2% | 0.00% | +50.0% |
Q4 2018 | $1,952,000 | -33.9% | 42,328 | +10.5% | 0.00% | -33.3% |
Q3 2018 | $2,953,000 | -1.9% | 38,293 | +7.1% | 0.00% | 0.0% |
Q2 2018 | $3,011,000 | +48.5% | 35,744 | +44.2% | 0.00% | +50.0% |
Q1 2018 | $2,027,000 | +57.0% | 24,786 | +9.8% | 0.00% | +100.0% |
Q4 2017 | $1,291,000 | -10.3% | 22,580 | +4.7% | 0.00% | -50.0% |
Q3 2017 | $1,439,000 | +37.3% | 21,565 | +5.9% | 0.00% | +100.0% |
Q2 2017 | $1,048,000 | -23.9% | 20,365 | -13.7% | 0.00% | -50.0% |
Q1 2017 | $1,378,000 | +51.1% | 23,602 | +8.0% | 0.00% | +100.0% |
Q4 2016 | $912,000 | -19.6% | 21,847 | +1.7% | 0.00% | -50.0% |
Q3 2016 | $1,135,000 | +18.2% | 21,483 | -6.2% | 0.00% | 0.0% |
Q2 2016 | $960,000 | +42.9% | 22,915 | +38.4% | 0.00% | +100.0% |
Q1 2016 | $672,000 | +48.3% | 16,561 | +137.3% | 0.00% | 0.0% |
Q4 2015 | $453,000 | -33.9% | 6,980 | -28.1% | 0.00% | 0.0% |
Q3 2015 | $685,000 | +76.5% | 9,703 | +178.0% | 0.00% | 0.0% |
Q2 2015 | $388,000 | +79.6% | 3,490 | +52.3% | 0.00% | – |
Q1 2015 | $216,000 | – | 2,291 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
BB BIOTECH AG | 2,719,998 | $155,502,000 | 4.38% |
Casdin Capital, LLC | 295,000 | $16,865,000 | 4.11% |
Opaleye Management Inc. | 130,000 | $7,432,000 | 2.38% |
Opus Point Partners Management, LLC | 28,704 | $1,641,000 | 1.42% |
Fernwood Investment Management, LLC | 27,550 | $1,575,000 | 0.84% |
Rhenman & Partners Asset Management AB | 100,000 | $5,717,000 | 0.77% |
COLUMBIA WANGER ASSET MANAGEMENT LLC | 760,116 | $43,456,000 | 0.65% |
Eventide Asset Management | 214,000 | $12,234,000 | 0.64% |
DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | 262,984 | $15,035,000 | 0.59% |
CAPITAL GUARDIAN TRUST CO | 663,089 | $37,909,000 | 0.54% |